Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 35

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 35
---
 are an integral part of our executive compensation program, and comprise the primary “at-risk” portion of our named executive officer compensation package. These awards strongly align our executive officers’ interests with those of our stockholders by providing a continuing financial incentive to maximize long-term value for our stockholders and by encouraging our executive officers to remain in our long-term employ.

• We do not provide our executive officers with any excise tax gross ups.

• We do not provide executive fringe benefits or perquisites to our executives, such as car allowances.

• Our Compensation Committee has retained an independent third-party compensation consultant for guidance in making compensation decisions. We retained Alpine Rewards in 2022 to advise the Compensation Committee on market practices, including identifying a peer group of companies and their compensation practices, so that our Compensation Committee can regularly assess the Company’s individual and total compensation programs against these peer companies, the general marketplace and other industry data points.

• We prohibit hedging and pledging of Company stock. Please see the section titled “ Information Regarding the Board of Directors and Corporate Governance—Prohibition on Speculative Trading ” for further details.

#### Company Performance in 2024
We achieved significant growth during 2024 as we continued to expand the reach of our three commercial medicines within our patient communities and achieved total net product sales of $336.4 million for the year ended December 31, 2024. Our global Livmarli business grew to 30 countries with commercial access, including successful reimbursement negotiation and launch in the four major European markets.

Our pipeline also demonstrated success throughout 2024 with the approval of Livmarli by the FDA for cholestatic pruritus in progressive familial intrahepatic cholestasis (“PFIC”) patients and in Europe for treatment of PFIC and the positive interim results for volixibat in VISTAS primary sclerosing cholangitis and VANTAGE primary biliary cholangitis (“PBC”) studies. Volixibat was also granted breakthrough designation for the treatment of pruritus due to PBC based on the interim results. In October 2024 we also in-licensed global rights to PDE4D inhibitor MRM-3379 for Fragile X Syndrome.

Advisory “Say on Pay” and “Say on Frequency” Votes

At the 2024 Annual Meeting, we conducted our first advisory vote on our executive compensation program (commonly referred to as a “Say on Pay” vote), and of the shares present in person, virtually or represented by proxy and